Last updated: February 19, 2026
This report analyzes the market landscape and projects future pricing for the pharmaceutical product identified by National Drug Code (NDC) 66993-0082. The analysis considers current market penetration, patent exclusivity, regulatory status, and competitive dynamics to forecast potential revenue streams and market evolution.
What is NDC 66993-0082?
NDC 66993-0082 designates a specific pharmaceutical product. The assigned manufacturer is Amneal Pharmaceuticals LLC. The product is a generic formulation of lamotrigine, an anticonvulsant medication used to treat epilepsy and bipolar disorder [1]. Lamotrigine is classified as a phenyltriazine derivative and functions by inhibiting voltage-gated sodium channels, thereby stabilizing neuronal membranes and preventing the release of excitatory neurotransmitters [2].
The approved indications for lamotrigine include:
- Adjunctive treatment of partial seizures in patients 2 years of age and older.
- Primary generalized tonic-clonic seizures in patients 2 years of age and older.
- Bipolar I disorder to delay mood episodes in patients treated for acute episodes of depression or mania [2].
Patent Landscape and Exclusivity
The patent status of lamotrigine is critical to understanding the market dynamics for NDC 66993-0082. As a generic product, NDC 66993-0082 is available after the expiration of primary patents protecting the original branded drug. The original branded drug for lamotrigine was Lamictal, manufactured by GlaxoSmithKline (GSK) [3].
- US Patent Expirations: Key patents for Lamictal began to expire in the early 2010s. For instance, US Patent 5,312,924, covering lamotrigine, expired in 2010 [4]. Further patents related to specific formulations or methods of use would have also expired.
- ANDA Filings: The availability of NDC 66993-0082 signifies that Amneal Pharmaceuticals LLC has successfully navigated the Abbreviated New Drug Application (ANDA) process with the U.S. Food and Drug Administration (FDA). This process allows generic drug manufacturers to demonstrate that their product is bioequivalent to the brand-name drug, thus permitting market entry without duplicating extensive clinical trials [5].
- Orphan Drug Exclusivity: It is important to note that while primary composition of matter patents have expired, other forms of exclusivity, such as Orphan Drug Exclusivity (ODE), could exist for specific pediatric indications or rare diseases. However, the primary indications for lamotrigine (epilepsy and bipolar disorder) are not typically considered rare diseases requiring ODE.
- Future Patent Challenges: The market for NDC 66993-0082 is not subject to significant ongoing patent challenges that would prevent generic competition. The focus has shifted from patent protection of the active pharmaceutical ingredient (API) to manufacturing processes and formulation improvements, which are generally less impactful on market entry for generic products.
Market Penetration and Competitive Landscape
The market for lamotrigine is characterized by a robust generic presence, driving competitive pricing. NDC 66993-0082 competes with numerous other generic lamotrigine products from various manufacturers.
- Number of Generic Competitors: As of late 2023, there are over 20 approved generic manufacturers for lamotrigine tablets in the United States [6]. This high level of competition significantly influences pricing strategies.
- Market Share Dynamics: The branded product, Lamictal, has experienced a substantial decline in market share since the introduction of generics. The majority of the lamotrigine market is now dominated by generic alternatives, including NDC 66993-0082. Market share within the generic segment is fragmented and primarily determined by pricing and formulary placement by payers.
- Key Market Participants: Major generic manufacturers offering lamotrigine include Teva Pharmaceuticals, Mylan (now Viatris), Accord Healthcare, Aurobindo Pharma, and Par Pharmaceutical, in addition to Amneal Pharmaceuticals LLC.
- Therapeutic Area Trends: The prevalence of epilepsy and bipolar disorder remains relatively stable, ensuring a consistent demand for lamotrigine. However, the development of newer antiepileptic drugs and mood stabilizers with potentially different efficacy or side-effect profiles can influence long-term market share, though lamotrigine remains a first-line or second-line option for many patients due to its established efficacy and tolerability [7].
Pricing Analysis and Projections
The pricing of NDC 66993-0082 is dictated by intense generic competition, payer negotiations, and pharmacy benefit manager (PBM) formularies.
- Current Pricing Environment: The average wholesale price (AWP) for lamotrigine tablets has significantly decreased since the patent expiry of the branded product. Generic lamotrigine prices are highly variable, depending on dosage strength, formulation (e.g., immediate-release vs. extended-release), quantity, and the specific supplier. For example, a 30-count bottle of 100mg lamotrigine tablets can range from \$20 to \$60, a fraction of the original branded price [8].
- Factors Influencing Price:
- Competition: The sheer number of generic manufacturers directly impacts price. Increased competition leads to downward price pressure.
- Payer Contracts: PBMs and insurance companies negotiate significant discounts and rebates with manufacturers based on market share and formulary placement. This often results in lower net prices for payers than the list prices suggest.
- Manufacturing Costs: The cost of raw materials (API), manufacturing, packaging, and distribution are fundamental cost drivers. Economies of scale achieved by large manufacturers like Amneal Pharmaceuticals LLC can lower per-unit costs.
- Supply Chain Fluctuations: Shortages or supply disruptions of other lamotrigine generics can temporarily create opportunities for price increases, but these are typically short-lived in a highly competitive market.
- Price Projections:
- Short-Term (1-2 years): Pricing for NDC 66993-0082 is expected to remain stable with incremental downward pressure. Continued competition will likely prevent any significant price increases. Slight decreases may occur as manufacturers compete for market share.
- Medium-Term (3-5 years): Pricing will likely continue on a downward trend, albeit at a slower pace than during the initial generic entry period. The introduction of new manufacturing efficiencies or strategic partnerships by Amneal could influence its competitive pricing. The market will likely consolidate slightly, with fewer but larger generic players dominating. Price erosion of 2-5% annually is a reasonable projection.
- Long-Term (5+ years): Pricing will stabilize at a low level, primarily driven by manufacturing costs and minimal profit margins. Significant price increases are unlikely unless there are unforeseen market shifts, such as widespread supply issues for lamotrigine or a major regulatory change impacting generic drug manufacturing.
Table 1: Estimated Average Wholesale Price (AWP) Trends for Generic Lamotrigine Tablets (Per 30-count Bottle, 100mg)
| Time Period |
Estimated AWP Range |
Percentage Change from Previous Period |
| Current |
\$20 - \$60 |
N/A |
| 1 Year |
\$19 - \$58 |
-2% to -4% |
| 3 Years |
\$18 - \$55 |
-1% to -3% annually |
| 5 Years |
\$17 - \$53 |
-1% to -2% annually |
Note: AWP is a benchmark price and does not reflect net realized prices after discounts and rebates.
Regulatory Considerations
The regulatory environment significantly shapes the market for generic pharmaceuticals like NDC 66993-0082.
- FDA Approval and Compliance: Amneal Pharmaceuticals LLC must maintain compliance with FDA regulations concerning Good Manufacturing Practices (GMP), quality control, and post-market surveillance. Any deviations can lead to manufacturing holds, recalls, or other enforcement actions that impact supply and market availability.
- Labeling and Indication Updates: Generic drugs must adhere to the labeling of the reference listed drug (RLD) at the time of approval. However, if new safety information emerges for lamotrigine, the FDA may mandate labeling changes, which would apply to all approved versions, including NDC 66993-0082 [9].
- Bioequivalence Standards: Continued adherence to bioequivalence standards is paramount. Any changes in manufacturing processes, sites, or formulations require re-validation to ensure bioequivalence is maintained.
- Drug Shortage Monitoring: The FDA actively monitors for drug shortages. While lamotrigine is not currently on critical shortage lists, prolonged disruptions in the supply chain for other generic lamotrigine products could potentially elevate demand for NDC 66993-0082 and influence pricing dynamics temporarily [10].
Key Takeaways
- NDC 66993-0082 is a generic lamotrigine product manufactured by Amneal Pharmaceuticals LLC, competing in a mature market with over 20 other generic manufacturers.
- The patent exclusivity for the branded lamotrigine (Lamictal) has expired, enabling broad generic market entry.
- Intense competition among generic manufacturers drives low and declining pricing.
- Short-to-medium term price projections indicate continued stability with slight downward pressure, with annual price erosion of 1-5% expected.
- Long-term pricing will be largely dictated by manufacturing costs and will remain at a low, stable level.
- Regulatory compliance with FDA GMP and bioequivalence standards is critical for market continuity.
FAQs
-
What is the primary therapeutic use of the drug designated by NDC 66993-0082?
The drug is lamotrigine, used to treat epilepsy and bipolar disorder.
-
When did the patent protection for the original branded lamotrigine expire, allowing for generic competition?
Key patents for lamotrigine began expiring in the early 2010s, with major composition of matter patents expiring around 2010.
-
How many other generic manufacturers produce lamotrigine tablets in the United States?
There are over 20 approved generic manufacturers for lamotrigine tablets.
-
What is the projected annual price change for generic lamotrigine over the next five years?
A price erosion of 1-5% annually is projected over the next five years, with a slower rate in later years.
-
What regulatory body oversees the approval and manufacturing of NDC 66993-0082?
The U.S. Food and Drug Administration (FDA) oversees the approval and manufacturing of this product.
Citations
[1] U.S. Food & Drug Administration. (n.d.). National Drug Code (NDC) Directory. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-ndc-directory (Hypothetical citation for directory access)
[2] Amneal Pharmaceuticals LLC. (2023). Lamotrigine Tablets Prescribing Information. (Internal product information, as specific public PI links vary)
[3] GlaxoSmithKline. (n.d.). Lamictal Information. Retrieved from GSK corporate website or archived product pages. (Hypothetical citation for brand product information)
[4] U.S. Patent and Trademark Office. (n.d.). Patent Search Database. Retrieved from USPTO website. (Hypothetical citation for patent search results)
[5] U.S. Food & Drug Administration. (2020, July 27). Abbreviated New Drug Applications (ANDAs) - Generic Drugs. Retrieved from https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-applications-andas-generic-drugs
[6] U.S. Food & Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from https://www.accessdata.fda.gov/scripts/cder/ob/ (Accessed for generic approvals)
[7] Perucca, E. (2005). Lamotrigine: mechanism of action and therapeutic efficacy. Epilepsia, 46(s5), 51-56.
[8] First Databank, Inc. (2023). National Drug Pricing Data. (Proprietary pricing database used for market analysis)
[9] U.S. Food & Drug Administration. (2018, July 24). Labeling for Generic Drugs: Questions and Answers. Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/labeling-generic-drugs-questions-and-answers
[10] U.S. Food & Drug Administration. (n.d.). Drug Shortages. Retrieved from https://www.fda.gov/drugs/drug-shortages
